Trial Profile
Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Adefovir (Primary) ; Lamivudine (Primary) ; Telbivudine (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms TeSLA
- 09 Mar 2013 New trial record